Zyngenia, Inc. Appoints Frank Hsu, M.D., as Chief Medical Officer
08:45 EDT 31 May 2012 | PR Newswire
This article has expired, however you can still
download the PDF.
Preview:
GAITHERSBURG, Md., May 31, 2012 /PRNewswire/ -- Zyngenia, Inc., a biopharmaceutical company developing Zybodies (next-generation multi-specific antibody-based drugs) in oncology and immunology, announced today that it has appointed Frank Hsu...
Other Sources for this Article
More From BioPortfolio on "Zyngenia, Inc. Appoints Frank Hsu, M.D., as Chief Medical Officer"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
